A team of mathematical experts have said that 1729, which is also known as the Ramanujan-Hardy number, is linked to aspects of string theory and...
Achieving a breakthrough feat, a pharmaceutical company, Eli Lilly has claimed the development of a 'game changer' drug capable of effectively halting the rate of brain decline in patients suffering from Alzheimer's by about a third.
Eli Lilly informed about the promising trial results of its Alzheimer's drug, solanezumab, asserting that the wonder drug will substantially reduce the rate of the cognitive and functional decline in patients by about one third, specifically in patients with milder form of cognitive impairment.
Dr. Dean Hartley of Alzheimer's Association asserted that the new treatment will change the course of the disease and will make solanezumab significant for use as an everyday drug.
The initial study results were presented in a US conference and it was informed that a new trial is due to report next year in order to arrive at definitive evidence.
The development of the new drug is a milestone achieved in the research of Alzheimer's. The presently available medication for Alzheimer's like Aricept can manage only the symptoms of dementia. On the other hand, solanezumab attacks the deformed proteins, called amyloid that builds up in the brain during Alzheimer's.
Further, Dr. David Angus, Medical Contributor in CBS News informed that the new drug is an intravenous infusion given every four weeks. Angus stated, "Try the first drug to hit the underlying cause of the disease, rather than symptoms of the disease. So there's excitement and there's hope - two words you never hear with Alzheimer's".
However, Angus critically states that the previous two trials of the drug were effective only for those suffering with mild form of this disease.
